PROSTVAC Publications

Publications on or relating to PROSTVAC (PSA-TRICOM).

Gulley JL, Madan RA, Tsang KT, et al.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Cancer Immunol Res. 2014;2:133-141.
Mandl SJ et al.

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

Journal for ImmunoTherapy of Cancer 2014, 2:34
Mandl SJ, Rountree RB, Owen R, et al.

PROSTVAC, PSA-targeted poxvirus-based active immunotherapy: new evidence for mechanism of action.

J Clin Oncol. 2014;32:5s (suppl); Abstr 3080.
Shore ND

PROSTVAC® targeted immunotherapy candidate for prostate cancer

Immunotherapy. 2014;6(3):235-47.
Gulley JL, Madan RA, Stein WD, et al.

PSA-Tricom, a pox-viral vaccine in prostate cancer (PCa), alters tumor growth rates within 80 days after initiation in non-metastatic prostate cancer.

J Clin Oncol. 2013;31 (suppl 6): Abstract 57.
Heery CR, Madan RA, Bilusic M, et al.

A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.

J Clin Oncol. 2013;31(suppl 6): Abstract 102.
Kang TH, Mao CP, Lee SY, et al.

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor Immunity.

Cancer Res. 2013;73:2493-2504.
Malchow S, Leventhal DS, Nishi S, et al.

Aire-dependent thymic development of tumor-associated regulatory T cells.

Science. 2013;339:1219-1224
Rojan A, Funches R, Regan MM, et al.

Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

Clin Genitourin Cancer. 2013;11:362-364.
Schellhammer P, Chodak G, Whitmore JB, et al.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Urology. 2013;81:1297-1302.
Le DT, Jaffee EM.

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.

Cancer Res. 2012;72:3439-3444.
Madan RA, Mohebtash M, Arlen PM, et al.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Lancet Oncol. 2012;13:501-508.
Mandl SJ, Rountree RB, Dalpozzo K, et al.

Immunotherapy with MVA-BN®-HER2 induces HER 2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.

Cancer Immunol Immunother. 2012;61:19-29.
Bilusic M.

A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC).

J Clin Oncol. 2011;29(suppl 7): Abstract 163.
Bilusic M, Heery C, Madan RA.

Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Vaccine. 2011;29:6485-6497.
Gulley JL, Drake CG.

Immunotherapy for prostate cancer: recent advances, lessons learned and areas for further research.

Clin Cancer Res. 2011;17:3884-3891.
Heery C, Pinto PA, Schlom J, et al.

Intraprostatic vaccine administration in patients with locally recurrent prostate cancer.

J Clin Oncol. 2011;29(suppl 7): Abstract 141.
Gulley JL, Arlen PM, Madan RA, et al.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Cancer Immunol Immunother. 2010;59:663-674.
Kantoff P, Schuetz TJ, Blumenstein BA, et al.

Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

J Clin Oncol. 2010;28:1099-1105.
Chakraborty M, Wansley EK, Carrasquillo JA, et al.

The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.

Clin Cancer Res. 2008;14:4241-4249.